Human cytokine response to Texas crotaline envenomation before and after antivenom administration

American Journal of Emergency Medicine

Volumn 28, Issue 8, 2010, Pages 871-879

  Crocker, Patrick ^a   Zad, Omid ^b   Milling, Truman ^b   Maxson, Todd ^a   King, Benjamin ^b   Whorton, Elbert ^c  

^a Children's Medical Center   (United States)

^b University Medical Center Brackenridge   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; BETA2 GLYCOPROTEIN 1; CA 125 ANTIGEN; CYTOKINE; ENDOTHELIN 1; EOTAXIN; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES; SNAKE VENOM ANTISERUM; PEROXIDASE; SNAKE VENOM; VENOM ANTISERUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; ENVENOMATION; FEMALE; HUMAN; IMMUNOASSAY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SNAKE; SNAKEBITE; SNAKEBITE SEVERITY SCORE; VICTIM; AGKISTRODON; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CROTALUS; IMMUNOLOGY; MIDDLE AGED; SNAKE BITES; TIME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGKISTRODON; ANIMALS; ANTIVENINS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; CHILD; CHILD, PRESCHOOL; CROTALID VENOMS; CROTALUS; CYTOKINES; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERLEUKIN-4; MALE; MIDDLE AGED; PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SNAKE BITES; TEXAS; TIME FACTORS; YOUNG ADULT;

EID: 77957348064     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2009.04.038     Document Type: Article

References (40)

1. Avila-Aguero M.L., Paris M.M., and Hu S. Systemic cytokine response in children bitten by snakes in Costa Rica Pediatr Emerg Care 17 6 2001 425 429
2. Szold O., Weinbroum A.A., and Ben-Abraham R. Xanthine oxidase and tumor necrosis factor alpha: possible mediators of remote tissue injury after viper envenomation Isr Med Assoc J 2 11 2000 816 820
3. Dart R., Hurlburt K., and Garcia R. Validation of a severity score for the assessment of crotaline snakebite Ann Emerg Med 27 3 1996 321 326
4. Hurlburt K., Dart R., and Spaire D. Reliability of clinical presentation for predicting significant pit viper envenomation [abstract] Ann Emerg Med 17 1988 438 439
5. Russel F.E. Snake venom poisoning 1983 Scholium International Great Neck (NY)
6. Dart R.C., Seifert S.A., and Carroll L. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning Ann Emerg Med 30 1997 33 39
7. Bogdan G.M., McKinney P., and Porter R.S. Clinical efficacy of two dosing regimens of affinity purified mixed monospecific crotalid antivenom ovine Fab (CroTAb) [abstract] Acad Emerg Med 4 1997 518
8. Iyaniwura T.T. Snake venom constituents: biochemistry and toxicology (part 1) Vet Human Toxicol 33 1991 468 474
9. Iyaniwura T.T. Snake venom constituents: biochemistry and toxicology (part 2) Vet Human Toxicol 33 1991 475 480
10. Glenn J.L., and Straight R.C. Venom characteristics as an indicator of hybridization between Crotalus viridis viridis and Crotalus scutulatus scutulatus in New Mexico Toxicon 7 1990 857 862
11. Gregory V.M., Russell F.E., and Brewer J.R. Seasonal variations in rattlesnake venom proteins Proc West Pharmacol Soc 27 1984 233 236
12. Minton S.A., and Weinstein S.A. Geographic and ontogenic variation in venom of the Western diamondback rattlesnake (Crotalus atrox) Toxicon 24 1986 71 80
13. Snyder C.C. Antivenin activity of rattlesnake blood plasma Nature 261 1976 259 260
14. Retzios A.D., and Markalnd F.S. A direct-acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix: effects on various components of the human blood coagulation and fibrinolysis systems Thromb Res 52 1988 541 552
15. Zulys V.J., Teasdale S.J., and Michel E.R. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass Anesthesiology 71 1989 870 877
16. Curry S.C., and Kunkel D.B. Death from a rattlesnake bite Am J Emerg Med 3 1985 227 235
17. Kwaan H.C. Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism Thromb Diath Hemmor 56 suppl 1973 239 251
18. Dempfle C.E. Validation, calibration, and specificity of quantitative D-dimer assays Semin Vasc Med 5 4 2005 315 320 [Review]
19. Rucavado A., Escalante T., and Teixeira C.F. Increments in cytokines and matrix metalloproteinases in skeletal muscle after injection of tissue-damaging toxins from the venom of the snake Bothrops asper Mediators Inflamm 11 2 2002 121 128
20. Petricevich V.L., Teixeira C.F., and Tambourgi D.V. Increments in serum cytokine and nitric oxide levels in mice injected with Bothrops asper and Bothrops jararaca snake venoms Toxicon 38 9 2000 1253 1266
21. Sherry B., Tekamp-Olson P., and Gallegos C. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1-beta J Exp Med 168 1988 2251 2259
22. Lumpkins K., Bochicchio G.V., and Zagol B. Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury J Trauma 64 2 2008 358 361
23. Bengtsson G., and Olivecrona T. Human C-apolipoproteins promote hydrolysis of dimyristoyl phosphatidylcholine by snake venom phospholipase A2 FEBS Lett 140 1 1982 135 138
24. Walldius G., Jungner I., and Holme I. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
25. Lamarche B., Moorjani S., and Lupien P.J. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study Circulation 94 1996 273 278
26. Kawakami A., Aikawa M., and Libby P. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells Circulation 113 5 2006 691 700
27. Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
28. Pengo V., Brocco T., and Biasiolo A. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity Blood 94 11 1999 3814 3819
29. Hennerici M.G., Kay R., and Bogousslavsky J. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment With Ancrod Trial: a randomised controlled trial Lancet 368 9550 2006 1871 1878
30. Vincent J.L., Bernard G.R., and Beale R. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment Crit Care Med 33 10 2005 2266 2277
31. Donato N.J., Martin C.A., and Perez M. Regulation of epidermal growth factor receptor activity by crotoxin, a snake venom phospholipase A2 toxin. A novel growth inhibitory mechanism Biochem Pharmacol 51 11 1996 1535 1543
32. Joseph R., Pahari S., and Hodgson W.C. Hypotensive agents from snake venoms Curr Drug Targets Cardiovasc Haematol Disord 4 4 2004 437 459 [Review]
33. Lôbo de Araújo A., Kamiguti A., and Bon C. Coagulant and anticoagulant activities of Bothrops lanceolatus (Fer de lance) venom Toxicon 39 2-3 2001 371 375
34. Howard M., and Paul W.E. Interleukins for B lymphocytes Lymphokine Res 1 1 1982 1 4
35. Yokota T. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell-and T-cell-stimulating activities Proc Natl Acad Sci U S A 83 16 1986 5894 5898
36. Maeda S., and Yanagihara Y. Inflammatory cytokines (IL-4, IL-5 and IL-13) Nippon Rinsho 59 10 2001 1894 1899
37. Izuhara K., Arima K., and Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies Curr Drug Targets Inflamm Allergy 1 3 2003 263 269
38. Olver S., Apte S., Baz A., and Kienzle N. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? Tissue Antigens 69 4 2007 293 298
39. Walter M.R., Cook W.J., and Zhao B.G. Crystal structure of recombinant human interleukin-4 J Biol Chem 267 1992 20371 20376
40. Cook W.J., Ealick S.E., and Reichert P. Crystallization and preliminary x-ray investigation of recombinant human interleukin-4 J Mol Biol 218 1991 675 678